US pharma company Johnson and Johnson's COVID-19 vaccine to be manufactured in India by currently in phase 1/2 clinical trial phase cannot be directly channeled to the domestic market and will have to be handed over entirely to the US pharma giant as agreed by the firms but
The Central government is looking at the possibility of securing a part of Johnson and Johnson's COVID-19 vaccine, Times Now reported.
In India, the vaccine candidate, which is currently in phase 1/2 clinical trial phase, will be produced by Biological E.
However, the vaccine cannot be directly channeled to the Indian market and will have to be handed over entirely to the US pharma giant.
Hyderabad-based Biological E has proposed to manufacture about 30 crore doses of its indigenous vaccine exclusively for the Indian market by December and has sought "funding support" from the government.
However, the vaccine cannot be directly channeled to the Indian market and will have to be handed over entirely to the US pharma giantAs per reports, there are limited prospects of J&J exporting its vaccine from the US to other countries in the near future and the "entire production" at the BE facilities in India, beginning July/August, will be handed over to the pharma giant under a contract between the companies.
The Ministry of External Affairs (MEA), along with the Department of Biotechnology (DBT), has been asked to work on securing a part of the J&J vaccine to be manufactured by BE for the Indian market, the sources said.
The government is exploring all avenues to boost vaccine supply urgently to inoculate the billion-plus population amid a devastating second wave of COVID-19.
The Cabinet Secretary chaired two rounds of high-level meetings last week on the availability of the shots in the global as well as domestic markets.
Biological E is likely to start "fill and finish" of the J&J vaccine in July-August and manufacturing of the vaccine in the last quarter of the year.
The Development Finance Corporation of the United States is supporting BE for setting up three additional fill and finish lines, exclusively for J&J vaccine, and they plan to manufacture about 1 billion doses by the end of 2022, the sources said.